RxDoctor Payments Data

Sunil Patel, MD

Urology · Fairfax, VANPI 1366419202

Payments from drug & device makers

$829in general payments, 2019–2025

Across 26 payments — averaging $31.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$184
  • Boston Scientific$146
  • Bioprotect Medical, Inc.$114
  • AbbVie$65
  • Johnson & Johnson$58
  • Laborie Medical Technologies Corp.$56
  • plus $206 from 6 others

What the payments were for

  • Food & beverage$81498%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$829 in reported general payments places this provider in the 30th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$423,642
Medicare patients
915
Services billed
8,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron45$44,113
Tamsulosin Hcl918$19,432
GemtesaVibegron17$16,926
Methenamine Hippurate49$5,890
Potassium Citrate ErPotassium Citrate30$3,419
Tadalafil54$3,139
Finasteride200$2,749
Oxybutynin Chloride ErOxybutynin Chloride71$2,580
Alfuzosin Hcl ErAlfuzosin Hcl87$2,225
Cefdinir108$1,732
Solifenacin Succinate27$1,037
Dutasteride22$703
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav59$568
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$304
Doxycycline Hyclate25$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$15$44,11345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 300 urology providers in Virginia.

Other urology in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →